Beckman Coulter and Scopio Labs Add World's First Digital Bone Marrow Imaging and Analysis to Long-Term Partnership
Beckman Coulter and Scopio Labs have expanded their partnership to include a global distribution agreement for Scopio's Full-Field Bone Marrow Aspirate™ (FF-BMA) Application. This CE-Marked technology transforms bone marrow aspirate analysis by combining high-resolution Full-Field imaging with AI-powered decision support, integrated with Scopio's X100 and X100HT scanners. The application enables remote review of bone marrow smears, potentially reducing turnaround time and improving diagnostic confidence.
This expansion builds on their existing collaboration since 2022 to accelerate the adoption of digital cell morphology. In 2023, Beckman Coulter announced an end-to-end automated hematology solution connecting its DxH 900 Workcell and DxH Slidemaker Stainer II with Scopio's X100HT platform for AI-assisted peripheral blood smear analysis.
Beckman Coulter e Scopio Labs hanno ampliato la loro partnership per includere un accordo di distribuzione globale per l'applicazione Full-Field Bone Marrow Aspirate™ (FF-BMA) di Scopio. Questa tecnologia con marcatura CE trasforma l'analisi dell'aspirato del midollo osseo combinando imaging Full-Field ad alta risoluzione con supporto decisionale basato sull'IA, integrato con gli scanner X100 e X100HT di Scopio. L'applicazione consente la revisione remota degli strisci di midollo osseo, potenzialmente riducendo i tempi di risposta e migliorando la fiducia diagnostica.
Questa espansione si basa sulla loro collaborazione esistente dal 2022 per accelerare l'adozione della morfologia cellulare digitale. Nel 2023, Beckman Coulter ha annunciato una soluzione ematologica automatizzata end-to-end che collega il suo DxH 900 Workcell e il DxH Slidemaker Stainer II con la piattaforma X100HT di Scopio per l'analisi assistita da IA degli strisci di sangue periferico.
Beckman Coulter y Scopio Labs han ampliado su asociación para incluir un acuerdo de distribución global para la Aplicación Full-Field Bone Marrow Aspirate™ (FF-BMA) de Scopio. Esta tecnología marcada CE transforma el análisis del aspirado de médula ósea al combinar imágenes Full-Field de alta resolución con soporte de decisión impulsado por IA, integrada con los escáneres X100 y X100HT de Scopio. La aplicación permite la revisión remota de frotis de médula ósea, potencialmente reduciendo el tiempo de respuesta y mejorando la confianza diagnóstica.
Esta expansión se basa en su colaboración existente desde 2022 para acelerar la adopción de morfología celular digital. En 2023, Beckman Coulter anunció una solución de hematología automatizada de extremo a extremo que conecta su DxH 900 Workcell y DxH Slidemaker Stainer II con la plataforma X100HT de Scopio para el análisis de frotis de sangre periférica asistido por IA.
벡맨 쿨터(Beckman Coulter)와 스코피오 연구소(Scopio Labs)는 파트너십을 확장하여 스코피오의 전장 골수 흡인 애플리케이션(Full-Field Bone Marrow Aspirate™: FF-BMA)에 대한 글로벌 유통 계약을 체결했습니다. 이 CE 마크 기술은 고해상도 전장 이미지와 AI 기반 의사결정 지원을 결합하여 골수 흡인 분석을 변환하며, 스코피오의 X100 및 X100HT 스캐너와 통합되어 있습니다. 이 애플리케이션은 골수 도말검사의 원격 검토를 가능하게 하여, 잠재적으로 처리 시간을 단축하고 진단 신뢰성을 향상시킬 수 있습니다.
이번 확장은 디지털 세포 형태학의 채택을 가속화하기 위한 2022년부터의 기존 협력을 기반으로 하고 있습니다. 2023년에는 벡맨 쿨터가 AI 지원 말초 혈액 도말검사를 위한 스코피오 X100HT 플랫폼과 DxH 900 워크셀이자 DxH 슬라이드 메이커 스테이너 II를 연결한 엔드 투 엔드 자동화된 혈액학 솔루션을 발표했습니다.
Beckman Coulter et Scopio Labs ont étendu leur partenariat pour inclure un accord de distribution mondial pour l'application Full-Field Bone Marrow Aspirate™ (FF-BMA) de Scopio. Cette technologie marquée CE transforme l'analyse des aspirats de moelle osseuse en combinant imagerie Full-Field haute résolution avec un support décisionnel alimenté par l'IA, intégré aux scanners X100 et X100HT de Scopio. L'application permet l'examen à distance des frottis de moelle osseuse, ce qui peut potentiellement réduire les délais de réponse et améliorer la confiance diagnostique.
Cette expansion s'appuie sur leur collaboration existante depuis 2022 pour accélérer l'adoption de la morphologie cellulaire numérique. En 2023, Beckman Coulter a annoncé une solution automatisée d'hématologie de bout en bout reliant son DxH 900 Workcell et son DxH Slidemaker Stainer II à la plateforme X100HT de Scopio pour l'analyse assistée par IA des frottis de sang périphérique.
Beckman Coulter und Scopio Labs haben ihre Partnerschaft erweitert, um eine globale Vertriebsvereinbarung für die Full-Field Bone Marrow Aspirate™ (FF-BMA) Anwendung von Scopio einzuschließen. Diese CE-zertifizierte Technologie revolutioniert die Analyse von Knochenmarkaspiraten, indem sie hochauflösende Full-Field-Bilder mit KI-gestützter Entscheidungsunterstützung kombiniert, die mit den Scopio X100 und X100HT Scannern integriert ist. Die Anwendung ermöglicht die Fernüberprüfung von Knochenmarkausstrichen, was potenziell die Durchlaufzeiten verkürzt und das diagnostische Vertrauen erhöht.
Diese Erweiterung baut auf ihrer bestehenden Zusammenarbeit seit 2022 auf, um die Einführung digitaler Zellmorphologie zu beschleunigen. Im Jahr 2023 kündigte Beckman Coulter eine End-to-End-automatisierte Hämatologielösung an, die ihre DxH 900 Workcell und DxH Slidemaker Stainer II mit der X100HT-Plattform von Scopio für die KI-unterstützte Analyse von peripheren Blutausstrichen verbindet.
- Expansion of partnership with Scopio Labs to include global distribution of FF-BMA Application
- Introduction of first-of-its-kind digital bone marrow imaging and analysis solution
- Potential for reduced turnaround time and improved diagnostic confidence in bone marrow analysis
- Integration of AI-powered decision support system in bone marrow analysis workflow
- Continued advancement in digital transformation of clinical laboratories
- None.
Insights
This partnership expansion marks a significant leap in bone marrow aspirate (BMA) analysis. The integration of Scopio's Full-Field Bone Marrow Aspirate™ (FF-BMA) Application with Beckman Coulter's global distribution network could revolutionize hematology diagnostics. The AI-powered decision support system and high-resolution imaging offer potential for improved accuracy and reduced turnaround times.
The ability to review bone marrow smears remotely is a game-changer, potentially enhancing collaboration and facilitating second opinions. This could lead to better patient outcomes and more efficient use of specialist resources. However, it's important to monitor the system's performance against traditional methods to ensure diagnostic accuracy is maintained or improved.
The FF-BMA Application represents a significant technological advancement in hematology diagnostics. By combining high-resolution Full-Field imaging with AI-powered decision support, it addresses key challenges in traditional BMA analysis. The digital workflow integration with Scopio's X100 and X100HT scanners streamlines the process, potentially reducing human error and increasing efficiency.
The remote review capability via secure hospital networks is particularly noteworthy, as it aligns with the growing trend of telemedicine and remote diagnostics. This could lead to more efficient resource allocation and faster diagnoses, especially in areas with access to specialists. However, the success of this technology will depend on robust cybersecurity measures and seamless integration with existing hospital systems.
This partnership expansion signals strong market potential for digital cell morphology solutions. Beckman Coulter's decision to include Scopio's FF-BMA Application in its global distribution agreement indicates confidence in the technology's commercial viability. The move could significantly expand Scopio's market reach and accelerate adoption of digital hematology solutions worldwide.
For Beckman Coulter, this addition enhances its hematology portfolio, potentially strengthening its competitive position in the clinical diagnostics market. The partnership's focus on workflow benefits and remote viewing capabilities aligns well with current market trends towards digitalization and efficiency in healthcare. However, the success will depend on factors such as pricing strategy, training support and the ability to demonstrate clear ROI for laboratories adopting this technology.
Bone marrow aspirate analysis is a vital procedure providing essential information for the assessment of various hematologic diseases.i By aspirating a small sample of the liquid portion of bone marrow, clinicians can examine the cellular composition, as well as the morphology and maturity of the blood cells morphology. However, traditional BMA analysis uses manual, labor-intensive, time-consuming methods that are heavily reliant on highly skilled hematopathologists to ensure accuracy.
Scopio's FF-BMA Application transforms BMA analysis by combining high-resolution Full-Field imaging with a robust AI-powered decision support system into a fully digital workflow seamlessly integrated with Scopio's X100 and X100HT scanners. It also enables hematopathologists to review bone marrow smears remotely (via a secure hospital network), potentially reducing turnaround time, fostering collaboration, facilitating second opinions, and bolstering diagnostic confidence.
"In today's lab, there is limited technology available to assist in the analysis of bone marrow aspirate," said Chris Hagen, Senior Vice President and General Manager, Core Lab Specialty Products for Beckman Coulter Diagnostics. "With Scopio's technology, lab scientists can assess hundreds of cells to evaluate morphological features with the support of artificial intelligence using the world's first BMA digital imaging and analysis solutions. Reviewers can observe representative cell distribution across the sample at rates far exceeding that of reviews done by manual microscopes. We are thrilled to expand our partnership with Scopio and continue to bring full-field, AI-powered, digital imaging innovations to clinical labs worldwide."
"We are excited to extend our global partnership agreement with Beckman Coulter, which exemplifies our shared mission to advance the digital transformation of clinical laboratories around the world," said Itai Hayut, CEO and Co-Founder of Scopio Labs. "The addition of our first-of-its-kind digital bone marrow application into Beckman Coulter's hematology offering, signifies a strong endorsement of the successful adoption of Scopio's Full-Field digital cell morphology platform in the market to date. We look forward to continuing our partnership as Scopio brings new products to the market to fulfill the potential of hematology diagnostics in this new digital era."
Since 2022, Beckman Coulter and Scopio have been working together to accelerate adoption of the next generation of digital cell morphology. Scopio's X100 and X100HT digital cell morphology platforms employ full-field imaging and AI decision support eliminating the need for manual microscopy, while providing laboratory scientists and physicians true workflow benefits with simple to use remote viewing through a secured network.
In 2023, Beckman Coulter Diagnostics announced a new end-to-end automated hematology solution by connecting its DxH 900 Workcell and DxH Slidemaker Stainer II with the Scopio X100HT high-throughput digital cell morphology platform, complete with digitalized, AI-assisted peripheral blood smear analysis.
Availability of Scopio Labs' Full-Field Peripheral Blood Smear™ Application and Full-Field Bone Marrow Aspirate™ Application may vary by region. To learn more, visit www.beckmancoulter.com/scopio.
Follow and connect with Beckman Coulter via LinkedIn, X, and Facebook.
About Beckman Coulter Diagnostics
A global leader in advanced diagnostics, Beckman Coulter has challenged convention to elevate the diagnostic laboratory's role in improving patient health for nearly 90 years. Our mission is to Relentlessly Reimagine Healthcare, One Diagnosis at a Time – and we do this by applying the power of science, technology and the passion and creativity of our teams. Our diagnostic solutions are used in complex clinical testing, and are found in hospitals, reference laboratories and physician office settings around the globe. We exist to deliver smarter, faster diagnostic solutions that move the needle forward from what's now to what's next. We do this by accelerating care with an extensive clinical menu, scalable lab automation technologies, insightful clinical informatics, and optimize lab performance services. Beckman Coulter, part of the Danaher Corporation (NYSE:DHR) family of global science and technology companies. Headquartered in
About Scopio
Scopio Labs is the developer of full-field digital imaging for hematology diagnostics. By supporting laboratory scientists and clinicians with unprecedented scale and depth in digital cell morphology, the company's platforms enable timely detection of blood-related medical conditions, expediting patients' access to life-saving treatments.
Scopio solves cell morphology's age-old trade-off between resolution and field of view. Its high-resolution imaging and embedded AI combine for more efficient remote workflow, contributing to better diagnostics across the continuum of care.
Scopio Labs' Full-Field Peripheral Blood Smear Application and Full-Field Bone Marrow Aspirate Application are FDA-cleared and CE-marked for use with the Scopio X100 and Scopio X100HT platforms. To learn more, visit www.scopiolabs.com.
© 2024 Beckman Coulter. All rights reserved. Beckman Coulter, the stylized logo, and the Beckman Coulter product and service marks mentioned herein are trademarks or registered trademarks of Beckman Coulter, Inc. in
i Lewis JE, Pozdnyakova O. Digital assessment of peripheral blood and bone marrow aspirate smears. Int J Lab Hematol. 2023 Jun;45 Suppl 2:50-58. doi: 10.1111/ijlh.14082. Epub 2023 May 21. PMID: 37211430.
View original content to download multimedia:https://www.prnewswire.com/news-releases/beckman-coulter-and-scopio-labs-add-worlds-first-digital-bone-marrow-imaging-and-analysis-to-long-term-partnership-302249748.html
SOURCE Beckman Coulter Diagnostics
FAQ
What is the new product announced in Beckman Coulter and Scopio Labs' partnership expansion?
How does the FF-BMA Application improve bone marrow aspirate analysis?
When did Beckman Coulter and Scopio Labs start their partnership?
What automated hematology solution did Beckman Coulter announce in 2023?
